Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Visinorm is an ophthalmic nutraceutical developed by NutriMed Group, specifically formulated to support visual function and protect ocular tissues from oxidative damage. The product typically contains a combination of standardized herbal extracts and carotenoids, including anthocyanidins from bilberry (Vaccinium myrtillus), lutein, and zeaxanthin. Its mechanism of action is centered on providing antioxidant protection to the retina, enhancing microcirculation in the eye, and supporting the regeneration of rhodopsin, a light-sensitive pigment essential for vision in low-light conditions. Additionally, the carotenoid components act as a biological filter for high-energy blue light, thereby reducing the risk of light-induced damage to the macula. Visinorm is primarily indicated for individuals experiencing high visual strain, age-related vision changes, or as a preventative measure for retinal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Visinorm.